Bill > SF2806

This bill modifies Minnesota's prescription monitoring program (PMP) by updating terminology and expanding the scope of reportable substances. Specifically, the bill replaces the term "controlled substances" with "reportable substances" and now includes substances like gabapentin and FDA-approved opioid overdose reversal agents (opioid antagonists) in the reporting requirements. The bill makes several key changes to how prescription data is collected, accessed, and managed, including clarifying definitions, adjusting reporting requirements for dispensers, and modifying access rules for various professionals like prescribers, pharmacists, and law enforcement. The changes aim to improve tracking of prescription drug usage while maintaining patient privacy protections. Notable provisions include requiring prescribers to check the prescription monitoring database before issuing initial opiate prescriptions, establishing data retention and destruction protocols, and implementing safeguards for data access. The bill also restricts access to data on opioid antagonists to specific board personnel, reflecting a nuanced approach to managing sensitive prescription information.

Health and Social Services

https://www.revisor.mn.gov/bills/bill.php?b=Senate&f=SF2806&ssn=0&y=2025